The Filings Report

Oscar Health, Inc.

OSCRNYSECIK 1568651Healthcare / Healthcare Plansfiscal year ends December27 quarters since 2020

Revenue, Q3 FY2026
$5.1B
+72.1% on Q3 FY2025
Net income
$167M
+221.7% on Q3 FY2025
Free cash flow
−$1.2B
−24.5% on Q3 FY2025
Diluted EPS
$0.49
+192.5% on Q3 FY2025
Revenue, TTM
$17.5B
trailing four quarters
Net margin, TTM
4.9%
net income $855M
Free cash flow, TTM
$4.1B
$4.2B less $41M capex
Cash and equivalents
$4.5B
long-term debt $432M, Sep 30, 2026
Shares, 12-month change
+33.6%
346M diluted weighted shares (no single count on the cover), Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$10.6B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Oscar Health, Inc. reported revenue of $5.1B, +72.1% on Q3 FY2025, and net income of $167M (+221.7%). Operating margin was 3.5%. Free cash flow, operating cash flow less capital expenditures, was −$1.2B (−$1.2B less $11M). Diluted earnings per share were $0.49.

Share price

Daily candlesticks from November 11, 2024 to November 6, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

OSCR daily priceSplit-adjusted, US dollars; an earnings release
Nov 6, 2026O $32.89 · H $33.66 · L $30.06 · C $30.65 · −7.63% on the dayOver the range: +85.08%, Nov 7, 2025 to Nov 6, 2026
$9.02$17$25$32$40Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 5, 2026.

Revenue and net incomeRevenueNet income
−$2B$0$2B$4B$6BQ4'22, Revenue: $995MQ4'22, Net income: −$226MQ4'22Q1'23, Revenue: $1.5BQ1'23, Net income: −$40MQ1'23Q2'23, Revenue: $1.5BQ2'23, Net income: −$16MQ2'23Q3'23, Revenue: $1.4BQ3'23, Net income: −$65MQ3'23Q4'23, Revenue: $1.4BQ4'23, Net income: −$150MQ4'23Q1'24, Revenue: $2.1BQ1'24, Net income: $177MQ1'24Q2'24, Revenue: $2.2BQ2'24, Net income: $56MQ2'24Q3'24, Revenue: $2.4BQ3'24, Net income: −$55MQ3'24Q4'24, Revenue: $2.4BQ4'24, Net income: −$154MQ4'24Q1'25, Revenue: $3.0BQ1'25, Net income: $275MQ1'25Q2'25, Revenue: $2.9BQ2'25, Net income: −$228MQ2'25Q3'25, Revenue: $3.0BQ3'25, Net income: −$137MQ3'25Q4'25, Revenue: $2.8BQ4'25, Net income: −$353MQ4'25Q1'26, Revenue: $4.6BQ1'26, Net income: $679MQ1'26Q2'26, Revenue: $4.9BQ2'26, Net income: $362MQ2'26Q3'26, Revenue: $5.1BQ3'26, Net income: $167MQ3'26−$2B$0$2B$4B$6BQ4'22, Revenue: $995MQ4'22, Net income: −$226MQ4'22Q1'23, Revenue: $1.5BQ1'23, Net income: −$40MQ1'23Q2'23, Revenue: $1.5BQ2'23, Net income: −$16MQ2'23Q3'23, Revenue: $1.4BQ3'23, Net income: −$65MQ3'23Q4'23, Revenue: $1.4BQ4'23, Net income: −$150MQ4'23Q1'24, Revenue: $2.1BQ1'24, Net income: $177MQ1'24Q2'24, Revenue: $2.2BQ2'24, Net income: $56MQ2'24Q3'24, Revenue: $2.4BQ3'24, Net income: −$55MQ3'24Q4'24, Revenue: $2.4BQ4'24, Net income: −$154MQ4'24Q1'25, Revenue: $3.0BQ1'25, Net income: $275MQ1'25Q2'25, Revenue: $2.9BQ2'25, Net income: −$228MQ2'25Q3'25, Revenue: $3.0BQ3'25, Net income: −$137MQ3'25Q4'25, Revenue: $2.8BQ4'25, Net income: −$353MQ4'25Q1'26, Revenue: $4.6BQ1'26, Net income: $679MQ1'26Q2'26, Revenue: $4.9BQ2'26, Net income: $362MQ2'26Q3'26, Revenue: $5.1BQ3'26, Net income: $167MQ3'26−$2B$0$2B$4B$6BQ4'22, Revenue: $995MQ4'22, Net income: −$226MQ1'23, Revenue: $1.5BQ1'23, Net income: −$40MQ1'23Q2'23, Revenue: $1.5BQ2'23, Net income: −$16MQ3'23, Revenue: $1.4BQ3'23, Net income: −$65MQ3'23Q4'23, Revenue: $1.4BQ4'23, Net income: −$150MQ1'24, Revenue: $2.1BQ1'24, Net income: $177MQ1'24Q2'24, Revenue: $2.2BQ2'24, Net income: $56MQ3'24, Revenue: $2.4BQ3'24, Net income: −$55MQ3'24Q4'24, Revenue: $2.4BQ4'24, Net income: −$154MQ1'25, Revenue: $3.0BQ1'25, Net income: $275MQ1'25Q2'25, Revenue: $2.9BQ2'25, Net income: −$228MQ3'25, Revenue: $3.0BQ3'25, Net income: −$137MQ3'25Q4'25, Revenue: $2.8BQ4'25, Net income: −$353MQ1'26, Revenue: $4.6BQ1'26, Net income: $679MQ1'26Q2'26, Revenue: $4.9BQ2'26, Net income: $362MQ3'26, Revenue: $5.1BQ3'26, Net income: $167MQ3'26

Net income losses drawn in red.

Free cash flow
−$2B−$1B$0$1B$2B$3BQ4'22, Free cash flow: $144MQ4'22Q1'23, Free cash flow: $407MQ1'23Q2'23, Free cash flow: $160MQ2'23Q3'23, Free cash flow: −$1.2BQ3'23Q4'23, Free cash flow: $291MQ4'23Q1'24, Free cash flow: $628MQ1'24Q2'24, Free cash flow: $490MQ2'24Q3'24, Free cash flow: −$508MQ3'24Q4'24, Free cash flow: $340MQ4'24Q1'25, Free cash flow: $870MQ1'25Q2'25, Free cash flow: $500MQ2'25Q3'25, Free cash flow: −$974MQ3'25Q4'25, Free cash flow: $663MQ4'25Q1'26, Free cash flow: $2.6BQ1'26Q2'26, Free cash flow: $2.1BQ2'26Q3'26, Free cash flow: −$1.2BQ3'26−$2B−$1B$0$1B$2B$3BQ4'22, Free cash flow: $144MQ4'22Q1'23, Free cash flow: $407MQ1'23Q2'23, Free cash flow: $160MQ2'23Q3'23, Free cash flow: −$1.2BQ3'23Q4'23, Free cash flow: $291MQ4'23Q1'24, Free cash flow: $628MQ1'24Q2'24, Free cash flow: $490MQ2'24Q3'24, Free cash flow: −$508MQ3'24Q4'24, Free cash flow: $340MQ4'24Q1'25, Free cash flow: $870MQ1'25Q2'25, Free cash flow: $500MQ2'25Q3'25, Free cash flow: −$974MQ3'25Q4'25, Free cash flow: $663MQ4'25Q1'26, Free cash flow: $2.6BQ1'26Q2'26, Free cash flow: $2.1BQ2'26Q3'26, Free cash flow: −$1.2BQ3'26−$2B−$1B$0$1B$2B$3BQ4'22, Free cash flow: $144MQ1'23, Free cash flow: $407MQ1'23Q2'23, Free cash flow: $160MQ3'23, Free cash flow: −$1.2BQ3'23Q4'23, Free cash flow: $291MQ1'24, Free cash flow: $628MQ1'24Q2'24, Free cash flow: $490MQ3'24, Free cash flow: −$508MQ3'24Q4'24, Free cash flow: $340MQ1'25, Free cash flow: $870MQ1'25Q2'25, Free cash flow: $500MQ3'25, Free cash flow: −$974MQ3'25Q4'25, Free cash flow: $663MQ1'26, Free cash flow: $2.6BQ1'26Q2'26, Free cash flow: $2.1BQ3'26, Free cash flow: −$1.2BQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6BQ4'22, Cash and equivalents: $1.6BQ4'22, Long-term debt: $298MQ4'22Q1'23, Cash and equivalents: $2.1BQ1'23, Long-term debt: $298MQ1'23Q2'23, Cash and equivalents: $2.3BQ2'23, Long-term debt: $298MQ2'23Q3'23, Cash and equivalents: $1.4BQ3'23, Long-term debt: $299MQ3'23Q4'23, Cash and equivalents: $1.9BQ4'23, Long-term debt: $299MQ4'23Q1'24, Cash and equivalents: $2.2BQ1'24, Long-term debt: $299MQ1'24Q2'24, Cash and equivalents: $2.3BQ2'24, Long-term debt: $299MQ2'24Q3'24, Cash and equivalents: $1.2BQ3'24, Long-term debt: $299MQ3'24Q4'24, Cash and equivalents: $1.5BQ4'24, Long-term debt: $300MQ4'24Q1'25, Cash and equivalents: $2.2BQ1'25, Long-term debt: $300MQ1'25Q2'25, Cash and equivalents: $2.6BQ2'25, Long-term debt: $300MQ2'25Q3'25, Cash and equivalents: $2.1BQ3'25, Long-term debt: $686MQ3'25Q4'25, Cash and equivalents: $2.8BQ4'25, Long-term debt: $430MQ4'25Q1'26, Cash and equivalents: $4.8BQ1'26, Long-term debt: $431MQ1'26Q2'26, Cash and equivalents: $4.1BQ2'26, Long-term debt: $432MQ2'26Q3'26, Cash and equivalents: $4.5BQ3'26, Long-term debt: $432MQ3'26$0$2B$4B$6BQ4'22, Cash and equivalents: $1.6BQ4'22, Long-term debt: $298MQ4'22Q1'23, Cash and equivalents: $2.1BQ1'23, Long-term debt: $298MQ1'23Q2'23, Cash and equivalents: $2.3BQ2'23, Long-term debt: $298MQ2'23Q3'23, Cash and equivalents: $1.4BQ3'23, Long-term debt: $299MQ3'23Q4'23, Cash and equivalents: $1.9BQ4'23, Long-term debt: $299MQ4'23Q1'24, Cash and equivalents: $2.2BQ1'24, Long-term debt: $299MQ1'24Q2'24, Cash and equivalents: $2.3BQ2'24, Long-term debt: $299MQ2'24Q3'24, Cash and equivalents: $1.2BQ3'24, Long-term debt: $299MQ3'24Q4'24, Cash and equivalents: $1.5BQ4'24, Long-term debt: $300MQ4'24Q1'25, Cash and equivalents: $2.2BQ1'25, Long-term debt: $300MQ1'25Q2'25, Cash and equivalents: $2.6BQ2'25, Long-term debt: $300MQ2'25Q3'25, Cash and equivalents: $2.1BQ3'25, Long-term debt: $686MQ3'25Q4'25, Cash and equivalents: $2.8BQ4'25, Long-term debt: $430MQ4'25Q1'26, Cash and equivalents: $4.8BQ1'26, Long-term debt: $431MQ1'26Q2'26, Cash and equivalents: $4.1BQ2'26, Long-term debt: $432MQ2'26Q3'26, Cash and equivalents: $4.5BQ3'26, Long-term debt: $432MQ3'26$0$2B$4B$6BQ4'22, Cash and equivalents: $1.6BQ4'22, Long-term debt: $298MQ1'23, Cash and equivalents: $2.1BQ1'23, Long-term debt: $298MQ1'23Q2'23, Cash and equivalents: $2.3BQ2'23, Long-term debt: $298MQ3'23, Cash and equivalents: $1.4BQ3'23, Long-term debt: $299MQ3'23Q4'23, Cash and equivalents: $1.9BQ4'23, Long-term debt: $299MQ1'24, Cash and equivalents: $2.2BQ1'24, Long-term debt: $299MQ1'24Q2'24, Cash and equivalents: $2.3BQ2'24, Long-term debt: $299MQ3'24, Cash and equivalents: $1.2BQ3'24, Long-term debt: $299MQ3'24Q4'24, Cash and equivalents: $1.5BQ4'24, Long-term debt: $300MQ1'25, Cash and equivalents: $2.2BQ1'25, Long-term debt: $300MQ1'25Q2'25, Cash and equivalents: $2.6BQ2'25, Long-term debt: $300MQ3'25, Cash and equivalents: $2.1BQ3'25, Long-term debt: $686MQ3'25Q4'25, Cash and equivalents: $2.8BQ4'25, Long-term debt: $430MQ1'26, Cash and equivalents: $4.8BQ1'26, Long-term debt: $431MQ1'26Q2'26, Cash and equivalents: $4.1BQ2'26, Long-term debt: $432MQ3'26, Cash and equivalents: $4.5BQ3'26, Long-term debt: $432MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 5, 2026.

Oscar Health, Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 5, 2026Q2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue5,1394,8804,6472,8052,9862,8643,0462,392+72.1%
Cost of revenue—————————
Gross profit—————————
Research and development—————————
Selling, general and administrative722691706511522534483466+38.4%
Operating income178389704(334)(129)(230)297(148)+237.7%
Other income (expense)2(1)0(20)(3)3(3)0+165.6%
Pretax income175383699(353)(139)(234)288(154)+225.9%
Income tax821200(2)(5)130+547.0%
Net income167362679(353)(137)(228)275(154)+221.7%
Diluted EPS ($)0.491.102.07—(0.53)(0.89)0.92—+192.5%
Diluted shares (millions)346333330—259256306——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 5, 2026.

Oscar Health, Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 5, 2026Q2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents4,4674,0764,8052,7742,1492,5992,2371,527+107.9%
Short-term investments3,0224,4801,9951,216888938751624+240.4%
Total current assets8,3169,3737,7774,6133,7634,3133,7752,845+121.0%
Total assets10,00911,2279,2906,3255,7466,3845,8444,840+74.2%
Total current liabilities7,3018,6907,1404,8633,9774,8664,1493,463+83.6%
Long-term debt432432431430686300300300−37.0%
Total liabilities7,7839,1727,6235,3454,7195,2234,5083,824+64.9%
Stockholders’ equity2,2232,0521,6649781,0241,1581,3331,014+117.0%
Shares outstanding (millions)—————————

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 5, 2026.

Oscar Health, Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 5, 2026Q2 FY2026ended Jun 30, 2026filed Aug 7, 2026Q1 FY2026ended Mar 31, 2026filed May 7, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 6, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 8, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow(1,201)2,0922,619672(965)509879347−24.5%
Capital expenditures1112999997+25.5%
Free cash flow (CFO − capex)(1,212)2,0812,610663(974)500870340−24.5%
Depreciation and amortization76787779−10.5%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 13, 2026.

Income statement

Oscar Health, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed May 14, 2021FY2019ended Dec 31, 2019filed May 14, 2021
Revenue11,7019,1785,8633,9641,839463488
Cost of revenue———————
Gross profit———————
Research and development———————
Selling, general and administrative2,0501,7561,4261,257265167111
Operating income(396)57(236)(590)(544)(402)(259)
Other income (expense)(23)0(7)2(1)——
Pretax income(437)33(267)(610)(571)(406)(259)
Income tax673(1)112
Net income(443)25(271)(606)(573)(407)(261)
Diluted EPS ($)(1.69)0.10(1.22)(2.85)(3.20)(14.16)(9.06)
Diluted shares (millions)2622662222121792929

Balance sheet

Oscar Health, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed May 14, 2021FY2019ended Dec 31, 2019filed May 14, 2021
Cash and equivalents2,7741,5271,8701,5591,104826337
Short-term investments1,2166246901,397587366—
Total current assets4,6132,8453,0614,1222,3061,870—
Total assets6,3254,8403,6014,5273,3222,272—
Total current liabilities4,8633,4632,4293,2641,8521,666—
Long-term debt4303002992980142—
Total liabilities5,3453,8242,7953,6341,9291,823—
Stockholders’ equity9781,0148048901,387(1,296)(945)
Shares outstanding (millions)———————

Cash flow statement

Oscar Health, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed May 14, 2021FY2019ended Dec 31, 2019filed May 14, 2021
Operating cash flow1,095978(272)380(182)223(165)
Capital expenditures36282629261426
Free cash flow (CFO − capex)1,058950(298)351(208)209(191)
Depreciation and amortization2932311515117
Share repurchases————003
Dividends paid———————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$27M
9 sales by 6 insiders; officers and directors $27M
Bought, twelve months
$12M
1 purchases by 1 insider; officers and directors $12M
Sold, twelve months
$150M
61 sales by 7 insiders; officers and directors $150M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 18, 2026Wittman Vanessa AmesDirectoropen-market sale10b5-125,000$32.24$806K112,121Sep 22, 2026
Sep 18, 2026Kushner JoshuaCo-Founder and Vice Chairman, Director, 10% ownerotherindirect6M$0.00—0Sep 18, 2026
Sep 18, 2026Kushner JoshuaCo-Founder and Vice Chairman, Director, 10% ownerotherindirect75,520$0.00—0Sep 18, 2026
Sep 18, 2026Kushner JoshuaCo-Founder and Vice Chairman, Director, 10% ownerotherindirect1M$0.00—1MSep 18, 2026
Sep 18, 2026Kushner JoshuaCo-Founder and Vice Chairman, Director, 10% ownerotherindirect5M$0.00—5MSep 18, 2026
Sep 18, 2026Kushner JoshuaCo-Founder and Vice Chairman, Director, 10% ownerotherindirect164,218$0.00—164,218Sep 18, 2026
Sep 18, 2026Kushner JoshuaCo-Founder and Vice Chairman, Director, 10% ownerotherindirect1M$0.00—0Sep 18, 2026
Sep 18, 2026Kushner JoshuaCo-Founder and Vice Chairman, Director, 10% ownerotherindirect5M$0.00—0Sep 18, 2026
Sep 18, 2026Kushner JoshuaCo-Founder and Vice Chairman, Director, 10% ownerotherindirect164,218$0.00—0Sep 18, 2026
Sep 18, 2026Thrive Partners II GP, LLC+8 moreDirector, 10% ownerotherindirect6M$0.00—0Sep 18, 2026
Sep 18, 2026Thrive Partners II GP, LLC+8 moreDirector, 10% ownerotherindirect75,520$0.00—0Sep 18, 2026
Sep 18, 2026Thrive Partners II GP, LLC+8 moreDirector, 10% ownerotherindirect1M$0.00—1MSep 18, 2026
Sep 18, 2026Thrive Partners II GP, LLC+8 moreDirector, 10% ownerotherindirect5M$0.00—5MSep 18, 2026
Sep 18, 2026Thrive Partners II GP, LLC+8 moreDirector, 10% ownerotherindirect164,218$0.00—164,218Sep 18, 2026
Sep 18, 2026Thrive Partners II GP, LLC+8 moreDirector, 10% ownerotherindirect1M$0.00—0Sep 18, 2026
Sep 18, 2026Thrive Partners II GP, LLC+8 moreDirector, 10% ownerotherindirect5M$0.00—0Sep 18, 2026
Sep 18, 2026Thrive Partners II GP, LLC+8 moreDirector, 10% ownerotherindirect164,218$0.00—0Sep 18, 2026
Sep 3, 2026Liang JanetPresident, Oscar Insuranceopen-market sale10b5-110,360$31.45$326K248,697Sep 8, 2026
Sep 3, 2026Baltrus VictoriaChief Accounting Officeropen-market sale10b5-1958$31.45$30K213,631Sep 8, 2026
Sep 3, 2026Blackley Richard ScottChief Financial Officeropen-market sale10b5-128,869$31.45$908K1MSep 8, 2026
Sep 3, 2026McAnaney AdamChief Legal Officeropen-market sale10b5-19,092$31.45$286K209,004Sep 8, 2026
Sep 3, 2026Schlosser MarioDirectoropen-market sale10b5-131,422$31.45$988K449,444Sep 8, 2026
Aug 28, 2026Schlosser MarioDirectorconversion150,000——630,866Aug 31, 2026
Aug 28, 2026Schlosser MarioDirectoropen-market sale150,000$30.79$5M480,866Aug 31, 2026
Aug 27, 2026Schlosser MarioDirectorconversion600,000——1MAug 31, 2026

Full insider history for Oscar Health, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Oscar Health, Inc., CIK 1568651 on EDGAR
Extract generated
November 8, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: not filed
Gross profit: not filed
Research and development: not filed
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): not filed

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/OSCR.json